Mayo Clinic Cancer Center (MCCC) Senior Leadership encompasses the Director, Deputy Director Clinical Affairs, Deputy Director MCCC Arizona, Deputy Director MCCC Florida, and 5 Associate Directors. There have been a number of changes since the last renewal. As part of a planned succession following the successful 2003 CCSG competitive renewal, Dr. Robert Diasio was recruited as Cancer Center Director in a national search initiated in mid 2005 culminating with his appointment effective September 1, 2006. Dr. Charles Erlichman, previously an MCCC Associate Director, was appointed Deputy Director for Clinical Affairs in late 2004. In his position as Deputy Director for Clinical Affairs, he has primary responsibility for overseeing and implementing integration of the Cancer Center's clinical research activities across all three sites. Also in late 2004, Dr. Robert Smallridge was formally appointed as Deputy Director for MCCC Florida;having previously been the acting Deputy Director. Dr. Rafael Fonseca, co-program leader of the Hematologic Malignancies Program, was appointed as Deputy Director for MCCC Arizona in July 2006 succeeding Dr. Laurence J. Miller who stepped down to focus on his responsibilities as Associate Dean for Research at Mayo Clinic and Director for Research at Mayo Clinic Arizona. Senior Leadership otherwise remains unchanged at the level of the Associate Directors with Dr. Ed Leof continuing as Associate Director for Basic Sciences, Dr. Gloria Petersen as Associate Director for Population Sciences, Dr. Robert Jenkins as Associate Director for Translational Research, Mr. Michael Pfenning as Associate Director for Administration and Dr. Lynn Hartmann as Associate Director for Education and Training. SENIOR/

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-36
Application #
8136972
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-03-01
Budget End
2011-02-28
Support Year
36
Fiscal Year
2010
Total Cost
$513,632
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Jahanseir, Khadijeh; Xing, Deyin; Greipp, Patricia T et al. (2018) PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. Int J Gynecol Pathol 37:537-546
Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567
Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066

Showing the most recent 10 out of 1129 publications